Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa

We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology 2011-12, Vol.136 (6), p.881-888
Main Authors: GUNIA, Sven, KOCH, Stefan, HAKENBERG, Oliver W, MAY, Matthias, KAKIES, Christoph, ERBERSDOBLER, Andreas
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma in Situ - diagnosis
Carcinoma in Situ - pathology
Diagnosis, Differential
Female
Gene Expression Profiling
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Receptor, ErbB-2 - biosynthesis
Receptor, ErbB-2 - genetics
Retrospective Studies
Urinary Bladder - metabolism
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - pathology
Urothelium - metabolism
Urothelium - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.
ISSN:0002-9173
1943-7722
DOI:10.1309/AJCPKUZ69LXZGFEA